YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents.
1. To better understand how it decreases plasma cholesterol and triglyceride levels, we evaluated the effect of (E)-2-[2-fluoro-2-(quinuclidin-3-ylidene)ethoxy]-9H-carbazole monohydrochloride(YM-53601) on lipogenic biosynthesis in the liver and lipid secretion from the liver in rats and hamsters. 2. Single administration of YM-53601 in cholestyramine-treated rats inhibited triglyceride and free fatty acid (FFA) biosynthesis at a similar dose range to that at which it inhibited cholesterol biosynthesis. YM-53601 inhibited both triglyceride and FFA biosynthesis in hamsters treated with cholestyramine. 3. YM-53601 by single oral administration decreased the enhanced plasma triglyceride levels in hamsters induced by an injection of protamine sulfate, which inhibits lipoprotein lipase (LPL) and consequently increases plasma very low-density lipoprotein (VLDL) triglyceride levels. YM-53601 also decreased the enhanced plasma triglyceride and cholesterol levels in hamsters treated with Triton WR1339, which also inhibits the degradation of VLDL. Plasma cholesterol was significantly decreased as soon as 1 h after single administration of YM-53601 in hamsters fed a normal diet. 4. This is the first report that a squalene synthase inhibitor suppresses lipogenic biosynthesis in the liver and cholesterol and triglyceride secretion from the liver in vivo. We therefore suggest that the mechanism by which YM-53601 decreases plasma triglyceride might include these effects. The finding that YM-53601 rapidly decreased plasma cholesterol suggests that this compound may be effective in decreasing plasma cholesterol levels early in the course of treatment of hypercholesterolemia in humans.
Cardiovascular Diseases Research, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co. Ltd, 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan. ugawa@yamanouchi.co.jp
Tohru
T
Ugawa
Hirotoshi
H
Kakuta
Hiroshi
H
Moritani
Osamu
O
Inagaki
Hisataka
H
Shikama
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D002784:Cholesterol / Q000096:biosynthesis* / Q000097:blood / Q000378:metabolism; D002792:Cholestyramine Resin / Q000494:pharmacology; D006224:Cricetinae; D013186:Farnesyl-Diphosphate Farnesyltransferase / Q000037:antagonists & inhibitors*; D005230:Fatty Acids, Nonesterified / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism; D008071:Lipoprotein Lipase / Q000037:antagonists & inhibitors; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008647:Mesocricetus; D011092:Polyethylene Glycols / Q000494:pharmacology; D011479:Protamines / Q000494:pharmacology; D011812:Quinuclidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014280:Triglycerides / Q000096:biosynthesis* / Q000097:blood / Q000378:metabolism
D000924:Anticholesteremic Agents; D005230:Fatty Acids, Nonesterified; D011479:Protamines; D011812:Quinuclidines; D014280:Triglycerides; C414830:YM 53601; D002792:Cholestyramine Resin; D011092:Polyethylene Glycols; D002784:Cholesterol; D013186:Farnesyl-Diphosphate Farnesyltransferase; D008071:Lipoprotein Lipase; C016811:tyloxapol